Well Lead(SH:603309) Sou Hu Cai Jing·2025-08-06 11:01Core Viewpoint - The company, Weili Medical, is currently facing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Weili Medical's stock closed at 14.18 yuan, down 1.87%, with a rolling PE ratio of 17.72 times and a total market capitalization of 4.153 billion yuan [1]. - The company ranks 39th in the medical device industry, which has an average PE ratio of 53.93 times and a median of 37.81 times [1][2]. - As of the 2025 semi-annual report, 16 institutions hold shares in Weili Medical, including 8 funds, 6 other institutions, 1 social security fund, and 1 insurance company, with a total shareholding of 161.66 million shares valued at 2.056 billion yuan [1]. Industry Summary - The medical device industry has a significantly higher average PE ratio of 53.93 times compared to Weili Medical's 17.72 times, suggesting that the company may be undervalued relative to its peers [2]. - The industry median PE ratio is 37.81 times, further highlighting the disparity between Weili Medical and the broader market [2]. - Other companies in the industry, such as Jiuan Medical and Yingke Medical, have PE ratios of 10.95 and 15.68 times, respectively, indicating a wide range of valuations within the sector [2]. Financial Performance - For the first half of 2025, Weili Medical reported revenue of 745 million yuan, a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17% year-on-year, with a gross profit margin of 45.04% [1].